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Endocrine Disorders: Principles of Management 
The Why and Wherefore of Fructosamine 
Daniel B. Mendlovic, MD,* Fred W. Whitehouse, MD,* and Craig C. Foreback, PhD* 
B efore measures of glycosylated hemoglobin (GH) were available, clinicians and researchers evaluating diabetic 
patients could only infer overall blood glucose control. Clini-
cians attempted to extrapolate glycemic control from occasional 
fasting or random blood glucose measurements, while research-
ers used indirect (and often inaccurate) parameters of control 
such as number of insulin injections per day. The introduction of 
the GH measurements in the mid t970s made possible accurate 
assessment of overall glycemia for a defined time period. Clini-
cians could assess the efficacy of therapeutic interventions, and 
investigators could accurately evaluate the influence of blood 
glucose control on any number of outcomes. In 1982, another 
measure of glycemic control, fructosamine (FA), was made 
available. Herein, we examine the clinical utility and interpreta-
tion ofthe GH and FA measurements. 
Overview 
Both GH and FA are measurements of the degree to which 
plasma proteins undergo irreversible, nonenzymatic glycosyla-
tion (Figure). Glycosytation proceeds at a rate proportional to 
the semm glucose at any time (1). Therefore, the higher the 
blood glucose throughout the life span of the protein, the more 
protein becomes glycosylated. In this way, the average blood 
glucose for a specific period of time, dictated by the life span of 
the protein, can be estimated. 
The clinician can compare the glycosylated protein measure-
ment with that obtained before or after clinical interventions, 
such as institution of oral hypoglycemic therapy or intensifica-
tion of an insulin program. These measurements can also be 
used to provide feedback to the patients about their metabolic 
control and perhaps to develop a "goal" tevel of control. 
In research studies, such as the Diabetes Control and Compli-
cations Trial, the glycosylated protein result can be used to strat-
ify patients into groups with various levels of control. 
Unfortunately, a specific average blood glucose value cannot 
be attributed to a specific value for a glycosylated protein, so 
only broad estimations of average blood glucose are possible 
(2). Therefore, GH and FA results should not be used as tests for 
the diagnosis of diabetes mellitus or other syndromes of glucose 
intolerance (3,4). 
That these measurements are tmly average readings is an-
other limitation. The same GH or FA value may result for a pa-
tient whose measured blood glucose levels are consistentiy 200 
mg/dL as for a patient whose measured blood glucose levels are 
too mg/dL half the time and 300 mg/dL the other half of the 
time. Oversimplified, this illustration does emphasize that mea-
surement of GH or FA does not replace the office measurement 
of blood glucose or self-monitoring of capillary blood glucose 
by the patient. Onty through actual measurements of blood glu-
cose can hypoglycemia or hour-to-hour variation in blood glu-
cose be detected and specific changes in insulin regimens be ra-
tionally prescribed. 
In summary, measurements of GH or FA are most useful for 
evaluating intermediate-term blood glucose control and assess-
ing the efficacy of therapeutic interventions that may affect con-
trot. They can also be used to compare the degree of overall 
glycemia in large groups of patients. They are an adjunct to, not 
a replacement for, traditional diagnostic and monitoring tech-
niques. 
Glycosylated Hemoglobin 
GH was the first glycosylated protein measurement clinically 
available and is therefore the most extensively studied and em-
ployed measure of metabolic control. A number of different he-
moglobin A subfractions are measurable, but the hemoglobin 
Ajf. component is the most widely reported because it com-
prises the majority of glycosylated hemoglobin and is least af-
fected by recent fluctuations in blood glucose (5). It assesses the 
overall blood glucose over a four- to eight-week period (6). 
Values are reported as a percentage of the total hemoglobin 
which is glycosylated. Normal ranges for GH differ in different 
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Figure—Display of the reversible nonenzymatic glycosytation of proteins to the aldimine 
form. These compounds spontaneously undergo an irreversible Amadori rearrangement to 
the more stable ketoamine compound. With the GH measurement, the protein involved is 
hemoglobin; with FA, it is a variety of serum proteins. 
Table 
Correlation of GH and FA in Diabetic Patients* 
Number of Correlation 
Study Patients Coefficient 
Allgrove & Cockrill (7) 61 diaberic r = 0.69 
30 control 
Baker et al (9) 42 diat)etic r = 0.82 
30 control 
Dominiczak et al (12) 77 diabetic r = 0.20 
Negoro et al (10) 53 diabetic r = 0.73 
93 control 
Smart etal (11) 204 diabetic r = 0.80 
Sobel & Abbassi (2) 33 diabetic r = 0.59 
Henry Ford Hospitalt 100 diabetic r = 0.69 
"Results of six studies in which the correlation of GH and FA in diabetic patients is re-
ported. The r value was statistically significant (P < 0.05) in all but the Dominiczak study. 
tUnpublished dala from Henry Ford Hospital show a good correlation between the two 
measurements. 
GH = glycosylated hemoglobin, FA = fructosamine. 
laboratories and with different assay techniques, tn comparing 
results with different normal ranges, it is he%t to compare the 
number of standard deviations from the mean of each value, 
rather than the absolute result. (In the assay being used at present 
at Henry Ford Hospital, a high-performance liquid chromatog-
raphy method employing ion-exchange columns, the mean is 
4.9% for nondiabetic control subjects and the standard deviation 
is 0.4%. So, the mean ± 2 standard deviations results in a "clas-
sic" normal range of 4.1% to 5.7%, A value of 8.1%, for exam-
pte, woutd be 8 standard deviations above the mean vatue for 
nondiabetics.) The use of GH as a measure of overall glycemia 
is limited because it is a difficult test to perform with precision 
and accuracy (7), is expensive, and can be misleading in patients 
with hemoglobinopathies or hemolytic anemias (5). In clinical 
practice, these represent rare but significant problems. 
Fructosamine 
The fructosamine assay measures a variety of serum proteins 
which, like hemoglobin, after glycosytation form ketoamines by 
the Amadori reaction (Figure). They are termed fructosamines 
because the sugar component of the compound is converted 
from glucose to fructose during formation of the ketoamine. 
These substances can serve as reducing agents in alkaline solu-
tion allowing for easy, rapid, and inexpensive laboratory mea-
surement (8). 
As shown in the Table, in most trials FA and GH measure-
ments correlate well, with correlation coefficient (r values) be-
tween 0.59 and 0.82 (2,7,9-11). In our experience at Henry Ford 
Hospital, we have also found a good correlation between GH 
and FA. In August 1988, we obtained simultaneous FA values 
in too consecutive diabetic subjects in whom a GH was ob-
tained. Among these subjects, the r value for the correlation of 
GH and FA results was 0.69. 
One study failed to note a significant correlation between the 
two measurements in a diabetic population, with an r value of 
0.20 (12). It is not clear why the two measurements did not cor-
relate in this study, although it is possible that these represent 
patients in whom metabolic control is fluctuating rapidly. 
In contrast to GH, FA reflects overall blood glucose control 
over the previous one to two weeks (2). This relatively short 
time frame is a major clinical limitation to the use of FA as an 
estimate of overall glycemia. Recent marked changes in glyce-
mic control can provide a false impression of longer term con-
trol. 
A tess common problem with the FA assay is characterized 
by situations of increased protein loss or turnover that may 
cause an inaccurately low value (7). 
A Comparison of GH and FA 
GH is the more widely used, studied, and accepted marker of 
glycemic control in diabetic patients. We feel that this experi-
ence grants the GH test an insurmountable advantage over FA, 
despite the former being more difficult and expensive to per-
form. Present standards of medical care for patients with diabe-
tes, as promulgated by the American Diabetes Association (13), 
state that a "GH be performed at least semiannually in all dia-
betic patients and preferably quarterly in insulin-treated diabetic 
patients and in non-insulin-treated patients with poor metabolic 
control." Since GH assesses blood glucose control over a one- to 
two-month time frame, obtaining a GH value more often than 
quarteriy is inappropriate in most clinical situations. The FA as-
say should be reserved for specific scenarios, as in the patient 
with a hemoglobinopathy or when short-term changes in glyce-
mic controt are required, as in the pregnant diabetic patient, tn 
most other situations, the GH is the preferred marker. 
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Summary 
GH and FA are useful monitors in the care of diabetic pa-
tients. For most situations, GH is the preferred test and should be 
routinely monitored. FA should be reserved for exceptional situ-
ations in which blood glucose control over one to two weeks 
must be assessed or in patients with a hemoglobinopathy. Pa-
tients with diabetes should be advised of their present GH level 
and the preferred goal. 
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